Peptides by condition · Muscles, bones, joints and skin
Peptides studied for knee pain and osteoarthritis
Checked against our study pages and the FDA labelsPublished by PepVault
Our library holds 3 study pages on knee pain and osteoarthritis: 2 in people (1 of them a meta-analysis or randomized trial), and 1 in animals. They studied 3 compounds, with this many study pages each: Retatrutide 1, BPC-157 1 and AOD-9604 1.
What the research on knee pain and osteoarthritis looks like
Knee osteoarthritis is the slow wearing of the cartilage that cushions the knee joint, bringing pain and stiffness, and it grows more common with age and extra weight. The peptide evidence on knees is thin and mixed in kind: a weight-loss trial that also tracked knee pain, a look back at clinic records of knee injections, and an animal study of cartilage.
Knee studies in people use pain scores that the patient fills in, sometimes on a standard questionnaire. Animal studies look at the cartilage itself under a microscope.
Pain is easily swayed by expectation, so a result without a placebo group is weak evidence. Losing weight by itself eases knee pain, which matters when reading a weight-loss trial’s knee results.

Model. Individual results vary.
The 3 studies, by compound
Grouped by the compound each study is filed under, and within each, strongest design first. Each line gives the design, who was studied, how many and the year, before the finding.
Retatrutide
1 in peopleFor knee pain and osteoarthritis, 1 of our study pages is filed under Retatrutide: 1 randomized trial in people. It enrolled 2,339 people and was published in 2026, in N Engl J Med.
Retatrutide has no FDA-approved product: Drugs@FDA lists no application for it, and FDA writes that it is not a component of any FDA-approved drug.
- Randomized trial in people · 2,339 people · 2026Retatrutide: up to 25.0% weight loss at 80 weeks in TRIUMPH-1
BPC-157
1 in peopleFor knee pain and osteoarthritis, 1 of our study pages is filed under BPC-157: 1 observational study in people. It enrolled 17 people and was published in 2021, in Altern Ther Health Med.
BPC-157 has no FDA-approved product: Drugs@FDA lists no application for it.
- Observational study in people · 17 people · 2021BPC-157: 14 of 16 reported knee pain relief in a chart review
AOD-9604
1 in animalsFor knee pain and osteoarthritis, 1 of our study pages is filed under AOD-9604: 1 animal study (rabbits). It was published in 2015, in Ann Clin Lab Sci.
AOD-9604 has no FDA-approved product: Drugs@FDA lists no application for it.
- Animal study in rabbits · 32 studied · 2015AOD-9604 knee injections lowered cartilage damage in rabbits
Side by side
For the 3 compounds on this page: studies in people, studies in animals or cells, the size of the largest study in people, and the FDA status from the labels our status pages read (a dash where they hold no record).
| Compound | In people | Animals or cells | Largest in people | FDA |
|---|---|---|---|---|
| Retatrutide | 1 | 0 | 2,339 | Not approved |
| BPC-157 | 1 | 0 | 17 | Not approved |
| AOD-9604 | 0 | 1 | — | Not approved |
- In people
- 1
- Animals or cells
- 0
- Largest in people
- 2,339
- FDA
- Not approved
- In people
- 1
- Animals or cells
- 0
- Largest in people
- 17
- FDA
- Not approved
- In people
- 0
- Animals or cells
- 1
- Largest in people
- —
- FDA
- Not approved
What the studies did not show
Each study page names its own limits. These are the questions still open, in the study pages’ words.
- Retatrutide: up to 25.0% weight loss at 80 weeks in TRIUMPH-1The trial included only adults without diabetes, and the knee and sleep apnea results come from smaller subgroups. It was funded by Eli Lilly.
- BPC-157: 14 of 16 reported knee pain relief in a chart reviewThis was a small look-back study with no control group, so it can't separate the peptide's effect from placebo, time or other care. Pain was self-rated by phone months after the shot, follow-up time varied, and the study used no standard tools to measure function, stiffness or quality of life.
- AOD-9604 knee injections lowered cartilage damage in rabbitsThis is a small, short study in rabbits with chemically induced knee damage, so it is not a result in people. It looked only at knee injections and did not test any other use of AOD-9604.
This page is a reading of published studies, not medical advice. A diagnosis, and what to do about it, is a conversation with a clinician.
Questions
Which peptides have been studied for knee pain and osteoarthritis?
Our 3 study pages on knee pain and osteoarthritis are filed under 3 compounds, with this many each: Retatrutide 1, BPC-157 1 and AOD-9604 1. Retatrutide, BPC-157 and AOD-9604 have the most, 1 each.
Have any been tested in people with knee pain and osteoarthritis?
Yes: 2 of the 3 were in people, 1 of them a meta-analysis or randomized trial (Retatrutide). The largest enrolled 2,339 people: “Retatrutide: up to 25.0% weight loss at 80 weeks in TRIUMPH-1” (2026).
Is any peptide FDA-approved for knee pain and osteoarthritis?
Not by the labels our status pages read: of the 3 compounds here with an FDA record, none has a use tied to knee pain and osteoarthritis.
How large were the studies in people on knee pain and osteoarthritis?
Of the 2 in people, all give their size on our pages: 1 had 1,000 people or more and 1 had fewer than 100. The largest, a randomized trial from 2026, enrolled 2,339.
What did the animal and cell studies on knee pain and osteoarthritis use?
1 animal study (rabbits), filed under AOD-9604. A result in animals or cells shows what to test next, not what happens in a person.
What is the newest study on knee pain and osteoarthritis here?
Of our study pages on knee pain and osteoarthritis, the newest is “Retatrutide: up to 25.0% weight loss at 80 weeks in TRIUMPH-1”, a randomized trial in people published in 2026.
How this page was built
A study page is listed here only where we read its question, design and finding and the study was about this condition: its subjects had the condition, or were an animal or cell model of it, and the study gave them the compound. A study that only mentions the condition is not listed.
Studies are grouped by the compound each is filed under and ordered by design: meta-analyses and randomized trials in people first, then other studies in people, then animals, then cells, and within a group by size and then by year. The FDA status comes from the labels our legal-status and brand pages read.